ArticleFrontiers in physiology2025
Identification of potential miRNA biomarkers for neurobrucellosis diagnosis.
Article in Frontiers in physiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Neurobrucellosis (NB) is a rare complication of brucellosis that presentis with a variety of clinical symptoms, complicating its diagnosis. This study aimed to analyze the microRNA (miRNA) profile of cerebrospinal fluid (CSF) in NB patients to identify potential biomarkers for NB diagnosis. Methods: Small RNA sequencing was utilized to identify differential expressed miRNAs (DEmiRNAs) in CSF samples from both control and NB patients (in-house cohort). The GSE107554 dataset (validation cohort) from the GEO database was used to validate the expression levels of these DEmiRNAs. Subsequently, LASSO regression analysis was conducted to construct a diagnostic risk score model based on common miRNAs identified in both the in-house and validation cohorts. Results: The study identified 51 DEmiRNAs between the control and NB groups, based on the data from the in-house cohort. Among these, four common miRNAs (miR-342-3p, miR-576-5p, miR-15b-5p and miR-499a-5p) were significantly elevated in the infection group compared to controls in both the in-house and validation cohorts. Subsequently, a novel NB diagnostic signature comprising two miRNAs (miR-576-5p and miR-499a-5p) was developed using the LASSO regression analysis. Receiver operating characteristic (ROC) analysis demonstrated the good diagnostic potential of this miRNA signature in both cohorts. RT-qPCR analysis indicated elevated levels of miR-576-5p and miR-499a-5p in CSF samples of NB patients compared to controls. Additionally, RT-qPCR results revealed decreased levels of VAV3 (vav guanine nucleotide exchange factor 3, a target of miR-499a-5p) and IGF1 (insulin like growth factor 1, a target of miR-576-5p) in the CSF samples of NB patients. Conclusion: Collectively, miR-576-5p and miR-499a-5p may serve as potential biomarkers for the diagnosis of NB.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.